Identifying Rare Genetic Variation In Obsessive-Compulsive Disorder

IDENTIFYING RARE GENETIC VARIATION IN OBSESSIVE-COMPULSIVE DISORDER Sarah B. Abdallah, Carolina Cappi, Emily Olfson, and Thomas V. Fernandez. Child Study Center, Yale University School of Medicine, New Haven, CT Obsessive-compulsive disorder (OCD) is a neuropsychiatric developmental disorder with known heritability (estimates ranging from 27%-80%) but poorly understood etiology. Current treatments are not fully effective in addressing chronic functional impairments and distress caused by the disorder, providing an impetus to study the genetic basis of OCD in the hopes of identifying new therapeutic targets. We previously demonstrated a significant contribution to OCD risk from likely damaging de novo germline DNA sequence variants, which arise spontaneously in the parental germ cells or zygote instead of being inherited from a parent, and we successfully used these identified variants to implicate new OCD risk genes. Recent studies have demonstrated a role for DNA copy-number variants (CNVs) in other neuropsychiatric disorders, but CNV studies in OCD have been limited. Additionally, studies of autism spectrum disorder and intellectual disability suggest a risk contribution from post-zygotic variants (PZVs) arising de novo in multicellular stages of embryogenesis, suggesting these mosaic variants can be used to study other neuropsychiatric disorders. In the studies presented here, we aim to characterize the contribution of PZVs and rare CNVs to OCD risk. We examined whole-exome sequencing (WES) data from peripheral blood of 184 OCD trio families (unaffected parents and child with OCD) and 777 control trios that passed quality control measures. We used the bioinformatics tool MosaicHunter to identify low–allele frequency, potentially mosaic single-nucleotide variants (SNVs) in probands (OCD cases) and in control children. We then applied the XHMM tool to 101 of the OCD trio families and to the 777 control trio families, all generated with the same capture library and platform, to identify CNVs. The rate of all single-nucleotide PZVs per base pair was not significantly different between OCD probands (4.90 x 10) and controls (4.93 x 10), rate ratio = 0.994, p = 1. The rate of likely-damaging PZVs (those altering a stop codon or splice site) also is not significantly different in OCD probands (1.45 x 10) than in controls (1.09 x 10), rate ratio = 1.33, p = 0.653. When examining CNVs, the proportion of children with at least one rare duplication or deletion is not significantly different between OCD cases (0.869) and controls (0.796), chi-square = 2.97, p = 0.0846. However, when considering deletions separately from duplications, the proportion of children with at least one rare deletion is higher in OCD trios (0.606) than in controls (0.448), chi-square = 8.86, p = 0.00292. Although we did not detect a higher burden of PZVs in blood in individuals with OCD, further studies may benefit from examining a larger sample of families or from looking for PZVs in other tissues. The higher rate of de novo deletions in cases vs. controls suggests they may contribute to OCD risk, but further work is needed to experimentally validate the detected CNVs. We hope to eventually use these CNVs to identify OCD risk genes that could provide jumping-off points for future studies of molecular disease mechanisms. Acknowledgements: Special thanks to my research mentor, Tom Fernandez, for supervising this thesis and to Emily Olfson for her advice and contributions to this work. They have been lovely, brilliant, and encouraging people to work with. I also have appreciated the encouragement from other members of the Child Study Center and their efforts to create a welcoming work environment. Thanks to my parents and friends for supporting my efforts to pursue this sort of work and helping me through the growing pains. Additional thanks to the Yale Office of Student Research for their support. The research included in this thesis was funded by grants from the Allison Family Foundation, Brain and Behavior Research Foundation (NARSAD), and the National Institute of Mental Health under award number R01MH114927 (TVF) and by research fellowship funding from the Howard Hughes Medical Institute, American Society for Human Genetics, and American Academy of Child and Adolescent Psychiatry (SBA).